Physiomics Announces License Agreement with Eli Lilly
News Apr 02, 2009
Under the terms of the agreement,Physiomics will license to Lilly a customised version of its “ModelPlayer” for in silico simulations of unspecified anticancer drugs and Lilly will have the option to purchase additional licenses.
Physiomics’ “ModelPlayer” is a stand-alone simulation platform used for in-house model development that can be out-licensed to partners to allow them to perform their own simulations using Physiomics’ models. It incorporates a range of features necessary for developing and calibrating models and simulating anticancer drugs.
Dr Christophe Chassagnole, COO of Physiomics, said:
‘We are delighted with the continued interest shown by Lilly in Physiomics’
technology. We hope that the capability for Lilly scientists to directly use Physiomics’ models will strengthen the quality of the interactions within our ongoing research collaborations. This is also an important commercial and technical milestone for Physiomics as this is the first time that we have out-licensed our technology.’
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE